Human T cell leukaemia virus type I-(HTLV-I) transformed cells are capable of stimulating the proliferation of normal T lymphocytes, or stimulating intedeukin 2 expression in Jurkat T lymphoid cells. This effect is mediated by the CD2/lymphocyte function-associated antigen 3 (LFA-3) adhesion/signalling pathway. The current work demonstrates that CD3 is also required for this effect, suggesting that the T cell receptor (TCR)/CD3 complex is mediating this effect. However, this effect does not appear to be due to a superantigen since no change in TCR expression was found after HTLV-I-mediated proliferation, nor was proliferation inhibited by an antibody against the specific TCR expressed on Jurkat cells (TCR Vfl8).
Hallmark features of human T cell leukaemia virus type I (HTLV-I) infection are the presence of a high percentage of activated T cells in the bloodstream and the spontaneous proliferation of peripheral blood mononuclear cells (PBMCs) in culture (Gessain et al., 1991; Gessain & Gout, 1992; Itoyama et al., 1988; Jacobson et al., 1988) . Ex vivo studies of PBMCs have shown that HTLV-I gene expression is associated with perpetual immune activation (Gessain et al., 1991; Tendler et al., 1990) . We and others demonstrated that virus-producing T cells could activate normal peripheral blood lymphocytes (PBLs) by direct cell contact without infection (Kimata &Ratner, 1991; Wucherpfennig et al., 1992) . This mitogenic activity appears to be T cell-associated as neither purified virions nor virus-producing sarcoma cells activated PBLs or Jurkat cells (Kimata et al., 1993) . Since few cells in the bloodstream are infected and expressing HTLV-I (Kimata &Ratner, 1991) , this T cellstimulating activity may in part explain how a low percentage of virus-producing cells can induce a persistently high level of immune activation that may result in adult T cell leukaemia/lymphoma (ATLL) or tropical spastic paraparesis/HTL¥-I-associated myelopathy (TSP/HAM).
We have demonstrated a requirement for the CD2/ lymphocyte function-associated antigen 3 (LFA-3) adhesion/signalling pathway for T cell activation by HTLV-I-infected T cells (Kimata et al., 1993) . Signalling through CD2 is generally insufficient for T cell activation, except when ligands recognizing two distinct epitopes on CD2 are applied (Dustin et al., 1989; Hunig et al., 1987; Meuer et al., 1984) . Instead, this pathway co-stimulates activation through the T cell receptor (TCR)/CD3 complex (Dustin et al., 1989; Bockenstedt et al., 1988; Bierer et al., 1988) . Thus, the requirement for the CD2/LFA-3 pathway may indicate that an HTLV-I protein is co-stimulating T cell activation with LFA-3 via CD2 alone or that a viral protein is being presented by infected T cells as processed antigen or superantigen through the TCR/CD3 complex. In this study, we investigated whether or not T cell activation by HTLV-I-producing T cells also requires the TCR/CD3 complex. The data suggest that CD3 participates in activation by HTLV-I-producing T cells but activation is not targeted for particular TCR Vfl-expressing cells. Furthermore, the HTLV-I Gag proteins, p19 gag and p24 gag, do not appear to participate in virus-mediated lymphocyte activation.
Proliferation assays were preformed with PBMCs from normal healthy adult donors, prepared as previously described (Kimata &Ratner, 1991) . Cells were resuspended in RPMI 1640 medium supplemented with 10 % heat-inactivated (56 °C) fetal bovine serum, 2 mMglutamine, 100 U/ml penicillin and 100 lag/ml streptomycin, seeded into plastic culture dishes and incubated at 37 °C for 2 h. Non-adherent cells were transferred into new plastic flasks and incubated at 37 °C for an additional 24 h. The remaining non-adherent cells were co-cultivated with fixed HTLV-I-producing and nonproducing T cell lines in the presence or absence of antibodies. For fixation, cell lines were treated for 1 h with 1% paraformaldehyde in PBS and washed twice with RPMI 1640 complete medium prior to co-cultivation. The dilutions of antibodies used in experiments aimed at inhibiting the proliferation-inducing activity of 0001-2300 © 1994 SGM virus-producing T cell lines were 1 : 100 for purified Fab fi'agments and ascites and 1 : 5 for conditioned hybridoma supernatants.
Induction of the proliferation of PBLs by fixed HTLV-I-producing T cells was carried out at a 1:1 ratio of stimulator to responder cells as previously described (Kimata et al., 1993) , except that the PBLs and fixed cells were co-cultivated for 6 days prior to the addition of 1 laCi of [3H]thymidine. Cells were harvested with a Skatron cell harvester and [3H]thymidine incorporation was determined by standard scintillation counting.
We previously demonstrated that antibodies to CD2 or LFA-3 could inhibit the activation of PBLs or Jurkat cells by HTLV-I-infected cell lines (Kimata et al., 1993) . Generally, the CD2 signalling pathway only augments antigen presentation through the TCR/CD3 complex (Dustin et al., 1989; Bockenstedt et al., 1988; Bierer et al., 1988) . Additionally, Jurkat cells are believed to be responsive to a particular antigen or superantigen reactive with TCR Vfl8 (Fraser et al., 1992; Herman et al., 1990) , the Vfl expressed on Jurkat cells. This raised the possibility that HTLV-I may specifically activate a subset of T cells bearing TCR V/~8 via a superantigen. Thus, to determine whether or not activation of T cells by HTLV-I-producing T cells occurred via the TCR and to determine whether T cells bearing TCR Vfl8 were preferentially activated, we co-cultivated PBLs with a paraformaldehyde-fixed virus-producing T cell line (MT2) in the presence and absence of antibodies to the TCR Vfl8 molecule (Table 1) (Tables 1 and 3 ). Similar observations have been made using other HTLV-I-positive and -negative T cell lines and different PBL donors (data not shown).
Since the anti-Vfl8 MAbs may not be capable of blocking T cell proliferation by superantigen, we also examined whether virus-producing T cell lines preferentially induced proliferation of TCR VflS-bearing T cells. We did not find in long term co-cultivation experiments of X-irradiated MT2 and MT4 cell lines with PBLs preferential expansion of T cells bearing the TCR Vfl8 molecule (data not shown). These data suggest that HTLV-I most likely does not encode a superantigen specific for VflS.
In order to determine whether HLA class II molecules participated in activation of T cells by HTLV-Iproducing T cell lines, we examined a MAb to mono- :~ Conditioned hybridoma supernatants containing MAb to the TCR V/% (JR.2 and JR. 1) chains were provided by O. Kanagawa. These antisera inhibited antigen-specific T cell activation at the concentrations used in these experiments. :~ The anti-class II antibody (2.06) was a conditioned hybridoma supernatant containing MAb to monomorphic HLA-DR, provided by O. Kanagawa, and was able to inhibit antigen-specific T cell activation in the concentration used in these experiments (Engleman et al., 1980) . morphic HLA-DR for the ability to neutralize the proliferation-inducing capacity of fixed MT2 and MT4 cells. As shown in Table 2 , the anti-HLA class II antibody did not neutralize the proliferation-inducing activity of either virus-producing T cell line. These data suggest that the activation of lymphocytes by HTLV-Iproducing T cells may be independent of HLA class II. Furthermore, they suggest that the proliferation-inducing capacity of virus-infected T cells is not due to a mixed lymphocyte reaction (MLR) involving macrophages/monocytes.
To confirm that the anti-TCR Vfl8 and anti-class II antisera were functional, we assessed the effect of the addition of these antisera to Raji cells presenting a superantigen to Jurkat cells (Fig. 1) . The superantigen was staphylococcal enterotoxin D (SED). T cell activation of Jurkat cells was monitored by transfection of an interleukin 2-(IL-2) luciferase reporter construct, as described by Fraser et al. (1992) . Neither Jurkat cells alone, nor the addition of only Raji cells led to a significant level of T cell activation over background levels. Addition of SED with Raji cells resulted in levels of luciferase activity > 30-fold above background levels. Control mouse IgG had no inhibitory activity, whereas the antibodies to TCR Vfl8 resulted in 85 to 96% inhibition. The anti-class II antibody inhibited superantigen stimulation of Jurkat cells by 40 %. These data suggest that the antisera had at least partial activity at inhibiting the superantigen stimulation of Jurkat cells.
To determine whether CD3 participated in the activation of PBLs by HTLV-I-producing T cells, fixed MT2 cells were co-cultivated with PBLs in the presence or absence of an anti-CD3 MAb Fab fragment (OKT3 Fab). Fig. 2 shows that the OKT3 Fab fragment inhibited proliferation induced by the fixed MT2 cells by 90 %, whereas a control Fab fragment had no significant effect. Similar observations have been made using other HTLV-I-producing T cell lines (MT4 and HUT102) and two other different PBL donors (data not shown).
Although Gag proteins are not generally exposed on the surface of infected cells, a defective Gag protein with superantigen activity has been described for the murine leukaemia/murine AIDS virus (Hugin et al., 1991) . The activity of this protein can be inhibited by a MAb to the murine leukaemia virus (MuLV) p30 Gag protein. Thus, antibodies to the Gag proteins were used to assess whether they participate in the HTLV-I-mediated T cell activation process. Table 3 shows that MAbs to the matrix protein, p19 gag, and capsid protein, p24 gag, do not inhibit the proliferation of PBLs induced by fixed MT2 cells. We have also tested HTLV-I patient antisera for the ability to neutralize the mitogenic activity of HTLV-I. In all cases, the results have been negative (data not shown), in agreement with the findings of Wucherpfennig et al. (1992) .
In this study, we examined whether or not the TCR/CD3 complex is used in the stimulation of normal T cells by HTLV-I-producing T cells. We and others have previously demonstrated that the CD2/LFA-3 activation pathway mediates this effect (Wucherpfennig et al., 1992; Kimata 'et al., 1993) . However, Wucherpfennig et al. (1992) suggested that intercellular adhesion molecule-(ICAM) 1/LFA-1 were required to co-stimulate T cell proliferation in a TCR/CD3-and HLA class I-and II-independent manner. Similar to their findings, antibodies to HLA class II did not inhibit proliferation of PBLs induced by HTLV-I-producing T cells. We also found that an anti-CD3 Fab fragment inhibited proliferation, suggesting that the mitogenic activity of HTLV-I is dependent on the TCR/CD3 complex. Since T cell activation by the CD2/LFA-3 pathway has been shown to co-stimulate or augment T cell activation via the TCR/CD3 complex (Dustin et al., 1988; Bierer et al., 1988; Bockenstedt et al., 1988) , it seems likely that T cell activation induced by HTLV-I-producing T cells also requires the TCR/CD3 complex but may not be restricted by HLA class II. Whether the anti-CD3 Fab inhibits engagement with CD3 or signalling through the antigen receptor complex or CD2 alone will not be easily determined since T cell activation through CD2 depends on the expression of a functional antigen receptor (Bockenstedt et al., 1988) . Specifically, signalling via the CD2 pathway requires expression of CD3( (Moingeon et al., 1992) .
We also investigated the possibility that HTLV-I may encode a superantigen specific for the TCR V]~8 chain. We previously demonstrated that the Jurkat T cell line could be activated by HTLV-I-infected T cell lines (Kimata et al., 1993) . Jurkat T cells express TCR Vfl8 molecules and are thought to respond to a particular antigen or superantigens recognizing V/~8 molecules (Fraser et al., 1992; Herman et al., 1990) . As it does not seem likely that Jurkat T cells are specifically activated in response to an HTLV-I antigen, we investigated whether HTLV-I-producing T cell lines specifically induced proliferation of TCR Vfl8-bearing cells. An antibody to Vfl8 failed to prevent the proliferation of PBLs by fixed HTLV-I-producing T cell lines, and Vfl8-bearing T cells were not preferentially activated and expanded in long term co-cultivation experiments of PBLs with irradiated HTLV-I-infected T cell lines. It therefore does not appear that HTLV-I encodes a superantigen specific for the TCR Vfl8 molecule.
Initial observations suggested that virion-associated Env protein gp46 was a T cell mitogen (Gazzolo et al., 1987) . Subsequent studies could not validate those observations, but instead demonstrated that the mitogenic activity was T cell-associated and mediated by cellular glycoproteins (Wucherpfennig et al., 1992; Kimata et al., 1993) . We also demonstrated that a neutralizing antibody to the Tax transcriptional transactivator protein did not block T cell proliferation. In this study, we further report that MAbs directed against p 19 gag and p24 gag did not inhibit proliferation of PBLs induced by HTLV-I-producing T cell lines. Thus, intact virus structural proteins or a cell surface-bound Tax protein may not be important in conferring mitogenic activity upon infected T ceils.
In conclusion, we identified that lymphocyte activation by HTLV-I-producing T cells requires the TCR/CD3 complex but is not restricted by HLA class II. Together with our previous studies (Kimata et al., 1993) , we have identified that CD2/LFA-3 and CD3 are important for the mitogenic activity of HTLV-I. A possible explanation for these data is a two-determinant model of T lymphocyte activation in which a surface-bound viral antigen directly engages with the antigen receptor, CD3, or CD2 to co-stimulate activation. This would account for the absence of a neutralizing effect by the anti-HLA class II MAb. Furthermore, it appears that the Gag and Env proteins do not act as T cell mitogens. Although Tax induces T cell proliferation in pre-stimtilated cells, it does not activate quiescent T lymphocytes (Marriott et al., 1991) . Therefore, efforts to identify the virus gene encoding the mitogenic factor should focus on defective gene products or other HTLV-I-encoded proteins. The recently identified novel HTLV-I proteins, Tof and Rof (Ciminale et al., 1992; Koralnik et al., 1992) , should be examined in this regard. An alternative possibility is that a viral protein modifies LFA-3 so that it alone is sufficient for the activation of T cells. The identification of the viral proteins mediating this process and the mechanism of its action will be facilitated by an infectious molecular clone of HTLV-I. Finally, definition of CD2, LFA-3 and now CD3 as contributing cell surface factors for HTLV-I-driven T cell activation by cell-to-cell contact provides a basis for understanding the role of lymphocyte adhesion in the pathogenesis of ATLL and/or HAM/TSP. Further studies of MAbs or Fab fragments targeted to these glycoproteins, or soluble CD2 or LFA-3 may provide new insights into the treatment of ATLL or HAM/TSP.
